HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    
Now Available: Top 10 Stocks for 2010

These powerful long-term stocks for 2010 have just been announced. Our top picks for 2009 generated a +34.1% return. Don’t miss out. Learn more now.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Top 10 Stocks
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


AMLN: Amylin Pharmaceuticals Inc - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

AMYLIN PHARMACEUTICALS INC (NASD)
AMLN 17.43 N/A (N/A%) Vol.  0 N/A ET

Day Low - High N/A - N/A
52wk Low - High 7.89 - 19.99
Avg Volume 4,821,697
Industry MED-BIOMED/GENE
Market Cap 2.47 B
Div - Yield 0.00 - 0.00
PE (forward)
PEG Ratio N/A
Current Year Est. -.83
EPS Last Year -1.21
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Buy12%
# 2Strong Sell50.23%
# 3Hold14%
# 4Sell3.97%
# 5Hold1.85%
S&P50012.22%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


downgraded 01/27/2010
Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 02/04/2010
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
AMYLIN PHARMACEUTICALS INC AMLN PREMIUM
GILEAD SCIENCES GILD PREMIUM
ABRAXIS BIOSCI ABII PREMIUM
CURIS INC CRIS PREMIUM
See all MED-BIOMED/GENE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 2.71
ABR (Last Week) 2.71
# of Recs in ABR 17
Average Target Price 19.81
Industry Rank by ABR 68 out of 217
Rank in Industry 128 out of 162
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate AMLN?
Buy
Sell
Find out what the Zacks Community
thinks of AMLN at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR AMLN
Zacks Blog: Alkermes Retains Neutral Rec
Feb 08, 2010
Zacks Equity Research: Report for AMLN
Feb 04, 2010
Zacks Blog: Amylin Misses Estimates
Jan 29, 2010
Zacks Blog: Amylin Impresses in Head-to-Head
Dec 16, 2009
Zacks Blog: Byetta Label Revised
Nov 27, 2009
Zacks Blog: Good News for Alkermes’ Pipeline
Nov 18, 2009
Zacks Blog: Zacks Analyst Blog Highlights: Clorox Company, Arena Pharmaceuticals, Vivus Inc., Orexigen Therapeutics and Amylin Pharmaceuticals
Nov 03, 2009
Zacks Blog: Amylin Strikes First on Obesity
Nov 02, 2009
More Zacks Commentary
NEWS
Amylin Pharmaceuticals Upward Momentum Looks to Continue (AMLN)
Feb 09, 2010
Amylin Pharmaceuticals (AMLN) Showing Bullish Technicals With Support At 16.19
Feb 08, 2010
Alkermes Testing its Version of Popular Schizophrenia Drug - TheStreet.com
Feb 04, 2010
SmarTrend's Trend Spotter Sees Continued Upward Momentum on Shares of Amylin Pharmaceuticals (AMLN)
Feb 03, 2010
Amylin Pharmaceuticals Reports 2009 Financial Results
Jan 27, 2010
Skymark Research Initiates Independent Research Coverage on Amylin Pharmaceuticals, Inc.
Jan 27, 2010
Conference Calls Today: 5 P.M. EST
Jan 27, 2010
Indices Roll Over into the Close
Jan 26, 2010
More News
EARNINGS ESTIMATES
  This Quarter
03/2010
Next Quarter
06/2010
This Year
12/2010
Next Year
12/2011
Average Estimate -0.29 -0.30 -0.83 -0.33
Number of Estimates 14 14 15 14
Low Estimates -0.36 -0.40 -1.19 -1.14
High Estimate -0.18 -0.16 -0.38 0.45
Year Ago EPS -0.34 -0.36 -1.20 -0.83
EPS Growth 14.08% 17.86% 30.61% 60.20%

More Estimates

COMPANY DESCRIPTION
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN injection and BYETTA injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over one thousand five hundred employees nationwide.

Full Company Report
FINANCIALS
EPS TTM -1.21
Sales 758.42
Net Income -186.26
Price/Earnings N/A
Price/Book 5.85
Price/Cash Flow N/A
Price/Sales 3.09


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2010 Zacks Investment Research